Tag: press

SAN FRANCISCO, July 18, 2025 (GLOBE NEWSWIRE) -- Sunrun (Nasdaq: RUN), the nation’s leading provider of clean energy as a subscription service, today announced it has priced a securitization of leases and power purchase agreements. The securitization is Sunrun’s fourteenth public securitization since 2015 and third issuance in 2025.

TORONTO, July 18, 2025 (GLOBE NEWSWIRE) -- Purpose Investments Inc. (“Purpose”) is pleased to announce distributions for the month of July 2025 for its open-end exchange traded funds and closed-end funds (“the Funds”).

Phoenix platform matches users with genetically similar people to predict which interventions actually work.

SAN CARLOS, Calif., July 18, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on July 17, 2025 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 138,190 shares of Iovance’s common stock to 20 new, non-executive employees.

TORONTO, July 18, 2025 (GLOBE NEWSWIRE) -- Optiva Inc. (TSX: OPT) ("Optiva" or the "Company"), a leader in powering the telecom industry with cloud-native billing, charging and revenue management software on private and public clouds, today announced that it has entered into a support agreement (the "Support Agreement") with holders ("Noteholders") of approximately 85% of its outstanding principal amount of 9.75% senior secured PIK toggle notes due July 20, 2025 (the "Notes").

NEW YORK and VIENNA, July 18, 2025 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, “HOOKIPA”), a clinical-stage biopharmaceutical company developing next-generation immunotherapeutics for the treatment of cancer and serious infectious diseases, today announced its intention to voluntarily delist from the Nasdaq Capital Market (“Nasdaq”) and to deregister its common stock under Section 12(b) and Section 12(g) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and suspend its reporting obligations under Section 15(d) of the Exchange Act.

SOUTH SAN FRANCISCO, Calif., July 18, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on July 16, 2025 it granted stock options to purchase an aggregate of 131,683 shares of common stock and 88,755 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting to 18 employees, whose employment commenced in June and July 2025 as a material inducement to their employment.